Rasburicase Real-World Usage for the Prevention and Treatment of Tumor Lysis Syndrome in Adults and Children
In the adult and pediatric population, a single rasburicase dose of 0.15 to 0.2 mg/kg, capped at 6 mg, represents an effective, safe, and more cost-effective option for both the prevention and treatment of TLS. Further studies are warranted to compare single versus multiple dosing in pediatric populations and to identify potential risk factors for nonresponders.
Authors
- Isabelle Laverdière (ORCID: https://orcid.org/0000-0003-3972-6602)
- Louis-Philippe Grenier (ORCID: https://orcid.org/0009-0007-6718-6160)
- Julien Valois-Demers
- Émilie Bergeron (ORCID: https://orcid.org/0009-0004-6099-4008)
- Sandra Labonté
Institutions
- Centre hospitalier de l'Université Laval (CA)
- Université Laval (CA)
Publication Details
- Journal
- Annals of Pharmacotherapy
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1177/10600280251391871
- Primary Topic
- Methemoglobinemia and Tumor Lysis Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00